As part of the TVNIM-AFU registry, Laboratoire Cerba has partnered with the French Association of Urology (AFU) and Oncodiag to develop a CE-marked molecular test based on the analysis of a urine sample for personalized monitoring of patients treated for Non-Muscle Invasive Bladder Cancer (NMIBC) at low, intermediate, and high risk of recurrence.

The objective of this registry is to demonstrate that this new test could help reduce the frequency of cystoscopies.